{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:15:06Z","timestamp":1791875706460,"version":"4.3.4"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) remains a challenging condition, especially in patients with moderate-to-severe disease. Risankizumab (RZB), an anti-IL-23p19 monoclonal antibody, has shown efficacy in clinical trials. However, real-world data (RWD) in Asian populations are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess the effectiveness and safety of Risankizumab in Asian patients with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Multicenter cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study enrolled adult patients with moderate-to-severe CD who received Risankizumab between September 2024 and May 2025 in Taiwan. Efficacy was assessed at weeks 4, 8, and 12 using CD Activity Index (CDAI), patient-reported outcomes-2 (PRO2), and inflammatory bowel disease (IBD)-disk scores. Safety outcomes and treatment response by prior biologic exposure, including Ustekinumab (UST), were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-nine patients (mean age 41.5\u2009years, 69.4% male) were included. Clinical response rates were 53.1%, 75.5%, and 91.8% at weeks 4, 8, and 12, respectively; clinical remission was achieved in 12.2%, 22.4%, and 42.9%. PRO2 remission reached 53.5% by week 12. Both CDAI and IBD-Disk scores improved at weeks 4, 8, and 12 with statistical significance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Transmural healing was observed in 16.3% of patients at week 12. Clinical remission at week 12 was consistent regardless of prior Ustekinumab exposure (exposed 36.36% vs na\u00efve 44.74%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.630) or biologic-na\u00efve status (exposed 36.84% vs na\u00efve 63.63%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.119). No severe adverse events were reported, but mild events included headache and transient liver enzyme elevation (each 2.04%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Risankizumab may demonstrate significant short-term efficacy and favorable safety in real-world treatment of moderate-to-severe CD in an Asian cohort. Long-term data are needed to confirm sustained outcomes and guide their optimal use across diverse CD populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848251375844","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:46:50Z","timestamp":1758883610000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of Risankizumab for moderate-to-severe Crohn\u2019s disease: first Asian real-world data (STAR trial)"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-4958","authenticated-orcid":false,"given":"Chen-Shuan","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, No. 21, Nanya South Road, Banciao District, New Taipei City 220, Taiwan. Program A, Department of Electrical Engineering, Yuan Ze University, Taoyuan, Taiwan"},{"name":"Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-6248","authenticated-orcid":false,"given":"Chia-Jung","family":"Kuo","sequence":"additional","affiliation":[{"name":"Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan, Taiwan"},{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan"},{"name":"Inflammatory Bowel Disease Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Wei","family":"Chou","sequence":"additional","affiliation":[{"name":"Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Hsu","sequence":"additional","affiliation":[{"name":"Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Wang","family":"Chang","sequence":"additional","affiliation":[{"name":"Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puo-Hsien","family":"Le","sequence":"additional","affiliation":[{"name":"Taiwan Association for the Study of Intestinal Diseases, 5, Fu-Hsin Street, Guei-Shan District, Taoyuan City 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-0673.2003.01727.x"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl240172"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S492079"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00360-x"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00096"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08518-2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.076"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae091"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18294"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.10.001"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.208"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0211-1"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909094"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.1.65"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0810456"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.05.008"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa216"},{"issue":"4","key":"e_1_3_4_23_2","first-page":"1","article-title":"Progressing advanced therapies for inflammatory bowel disease: current status including dual biologic therapy and discontinuation of biologics","volume":"19","author":"Yashima K","year":"2025","unstructured":"Yashima K, Kurumi H, Yamaguchi N, et al. Progressing advanced therapies for inflammatory bowel disease: current status including dual biologic therapy and discontinuation of biologics. Expert Rev Gastroenterol Hepatol 2025; 19(4): 1\u201320.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380514"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20036"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.45"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18049"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad315"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.04.016"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17358"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae248"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.033"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.09.027"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2024-102809"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251375844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251375844","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251375844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T01:15:07Z","timestamp":1759194907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251375844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["10.1177\/17562848251375844"],"URL":"https:\/\/doi.org\/10.1177\/17562848251375844","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"17562848251375844"}}